Want to see DRMA full AI Analyst Report?
DRMA Stock Chart & Stats
$1.72
-$0.02(-1.52%)
At close: 4:00 PM EDT
$1.72
-$0.02(-1.52%)
Day’s Range― - ―
52-Week Range$0.95 - $4.84
Previous CloseN/A
Volume20.28K
Average Volume (3M)33.05K
Market Cap
$4.50M
Enterprise Value$775.80K
Total Cash (Recent Filing)$4.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.39
Shares Outstanding4,022,143
10 Day Avg. Volume24,832
30 Day Avg. Volume33,054
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio-0.28
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$4.00Price Target Upside132.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces interest expense and solvency pressure while preserving flexibility for operating decisions. This is particularly valuable for a development-stage company that must fund research and commercialization without adding fixed repayment obligations.
Focused Dermatology PlatformA focused platform addressing chronic skin diseases can concentrate research resources, clinical expertise, and future commercialization efforts within dermatology. Multiple candidates also create more than one potential path toward partnership, licensing, or eventual product revenue.
Initial Commercialization And FundingThe financing supports consumer research, pre-launch and launch activities, and working capital as Dermata moves beyond a purely clinical model. Combined with the planned Tome launch, this creates an early commercial pathway and a potential foundation for future customer and revenue development.
Bears Say
No Reported RevenueThe absence of reported revenue means Dermata has not yet demonstrated commercial demand or operating leverage from its products. Until sales develop, the company remains dependent on financing or future licensing outcomes to support its business and advance its pipeline.
Persistent Losses And Cash BurnPersistent operating losses are translating into substantial cash outflows, leaving the company reliant on external capital while it funds development and commercialization. Continued burn can constrain strategic flexibility and increase the importance of successfully executing its transition to revenue.
Declining And Thin Equity BaseA smaller equity base reduces the balance-sheet cushion available to absorb continued losses or fund initiatives internally. Because the company remains unprofitable and cash-flow negative, further erosion could increase dependence on additional financing and weaken financial resilience.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $0.95 and its highest was $4.84 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $4.50M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 39 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.55 by -$0.19.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 4,022,143 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.55. Following the earnings report the stock price went up 27.778%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
DRMA Stock 12 Month Forecast
Average Price Target
$4.00
▲(132.56% Upside)
Technical Analysis
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
25.41% Insiders
0.56% Mutual Funds
0.79% Other Institutional Investors
73.24% Public Companies and
Individual Investors